APOLLO PHARMA R&D (GFI)

Projektträger – zwischengeschaltetes Finanzinstitut

Pharmathen SA

Ort

• Griechenland

Beschreibung

The project concerns the development of novel generic drugs using the group's proprietary technological expertise.

Ziele

Research, development and innovation (RDI) activities fall within the scope of the Horizon 2020 Industrial Leadership (Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology) and Societal Challenges (Health, Demographic Change and Wellbeing) programme sections. EIB financing of the project corresponds to the Community's role to encourage research and technological development as defined in Article 179 of the EC Treaty and with the "Common Interest" criterion under the Treaty's Article 309 point (c), i.e. the Bank's financing activities under the Knowledge Economy (i2i), research & development.

Kommentar(e)

InnovFin – EU Finance for Innovators is a joint initiative launched by the EIB in cooperation with the European Commission under Horizon 2020. InnovFin consists of a series of integrated and complementary financing tools and advisory services covering the entire value chain of research and innovation in order to support investments from the smallest to the largest enterprise.

Sektor(en)

• Industrie - Verarbeitendes Gewerbe/Herstellung von Waren

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 25 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 50 million

Umweltaspekte

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU.

Auftragsvergabe

The promoter is a private company not operating in the utilities sector and not having a status of a contracting authority. Thus, it is not covered by the EU directives on procurement.

Projektstatus

Unterzeichnet - 26/11/2014